Compare BridgeBio Pharma Inc (BBIO) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Wynn Resorts, Limited — how do they compare? BridgeBio Pharma Inc trades at $84.9 (market cap $16.46B), while Wynn Resorts, Limited trades at $97 (market cap $9.95B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Wynn Resorts, Limited pays a 1.04% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WYNN | |
|---|---|---|
Market Cap | $16.46B | $9.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $133.34 |
52-Week Low | $44.81 | $94.78 |
Enterprise Value | $18.02B | $20.32B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Wynn Resorts (WYNN) trades at $97.13, down 2.65% today, amid bearish technical signals and recent earnings misses. The stock faces margin pressure despite revenue growth, with net income margin declining to 5.14% in 2025. Analyst consensus remains bullish with a $134.30 price target, though technical indicators show resistance near $99-$103. Recent news highlights Q2 2026 earnings anticipation and luxury segment strength.
Outlook: Long-term potential exists via luxury focus and Macau recovery, but near-term risks include debt load ($10.5B), competitive pressures, and volatile earnings. Investors should weigh high analyst optimism against technical weakness and margin trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
